Our present findings therefore offer novel insights into how SEMA6B affects prognosis and the immune microenvironment in CRC and suggests that SEMA6B may serve as a potential biomarker for developing immunotherapeutic strategies for assessing the efficacy and responsiveness of CRC treatments. The gene discussed is SEMA6B; the disease is colorectal carcinoma.